Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity. J of Skin 2023, 7 (6), s274. https://doi.org/10.25251/skin.7.supp.274.